DOCS Stock Falls -30% With A 6-day Losing Spree On Weak Guidance
Doximity (DOCS) – a cloud-based professional platform for U.S. medical professionals – hit a 6-day losing streak, with cumulative losses over this period amounting to -30%. The company’s market cap has crashed by about $2.0 Bil over the last 6 days and currently stands at $4.6 Bil.
The stock has YTD (year-to-date) return of 44.2% compared to -0.2% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity or a trap.
What Triggered The Slide?
[1] Disappointing Q4 Revenue Guidance
- Cash Machine Trading Cheap – Atlassian Stock Set to Run?
- Years of Rewards: $34 Bil From Union Pacific Stock
- Oracle Stock Hands $54 Bil Back – Worth a Look?
- International Business Machines Stock Hands $33 Bil Back – Worth a Look?
- Intuit Stock at Support Zone – Bargain or Trap?
- Trade Desk Stock Pulls Back to Support – Smart Entry?
- Q4 revenue projected at $143-$144M vs $150.2M estimate
- Projected growth decelerating to 4%
- Impact: Massive Post-Earnings Sell-Off, Sharp Drop in After-Hours Trading
[2] Multiple Analyst Price Target Cuts
- Barclays, BTIG, Needham, and others lowered price targets
- Concerns over slowing growth and AI-related costs
- Impact: Sustained Downward Price Pressure, Negative Institutional Sentiment
Opportunity or Trap?
Below is our take on valuation.
There is not much to fear in DOCS stock given its overall Strong operating performance and financial condition. Considering stock’s Moderate valuation, we think it is Attractive (For details, see Buy or Sell DOCS).
But here is the real interesting point.
You are reading about this -30% move after it happened. The market has already priced in the news. To avoid the next loser before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has a risk model designed to reduce exposure to losers.
Returns vs S&P 500
The following table summarizes the return for DOCS stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | DOCS | S&P 500 |
|---|---|---|
| 1D | -4.8% | -1.6% |
| 6D (Current Streak) | -29.9% | -0.7% |
| 1M (21D) | -40.3% | -1.9% |
| 3M (63D) | -53.1% | -0.2% |
| YTD 2026 | -44.2% | -0.2% |
| 2025 | -17.1% | 16.4% |
| 2024 | 90.4% | 23.3% |
| 2023 | -16.4% | 24.2% |
Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: DOCS Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 74 S&P constituents with 3 days or more of consecutive gains and 77 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 35 | 40 |
| 4D | 14 | 31 |
| 5D | 14 | 2 |
| 6D | 7 | 2 |
| 7D or more | 4 | 2 |
| Total >=3 D | 74 | 77 |
Key Financials for Doximity (DOCS)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $475.4 Mil | $570.4 Mil |
| Operating Income | $171.8 Mil | $230.1 Mil |
| Net Income | $147.6 Mil | $223.2 Mil |
Last 2 Fiscal Quarters:
| Metric | 2026 FQ2 | 2026 FQ3 |
|---|---|---|
| Revenues | $168.5 Mil | $185.1 Mil |
| Operating Income | $63.7 Mil | $71.9 Mil |
| Net Income | $62.1 Mil | $61.6 Mil |
The losing streak DOCS stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.